Prostate Cancer Program The Prostate Cancer Program (PCP) aims to advance and exploit scientific knowledge that will reduce the morbidity and mortality attributed to prostate cancer and lead to improvements in patients' quality of life. The PCP has three primary areas of focus where cooperative efforts (allocation of resources; faculty recruitments; scientific collaborations) are coordinated to make substantive advancements: 1) understanding the heritable and environmental risk factors contributing to prostate cancer development, progression, and lethality; 2) targeting mechanisms contributing to castration-resistant prostate cancer progression; and, 3) distinguishing lethal from indolent prostate cancer through discovery and validation of prognostic biomarkers and a treatment plan that affords longitudinal assessments and attenuation of risk. The P30 CCSG supports this research program by providing: key shared resources, particularly Comparative Medicine, Specimen Processing, Genomics, and Research Pathology; administrative and logistical support for PCP meetings, pilot funding for new clinical and translational research projects, and recruitment grants for new faculty. The Prostate Cancer Program currently has 32 members from 3 schools/divisions, 10 departments and 2 institutions. Eight members have primary appointments at FHCRC and 24 at UW. 29 Members (90%) have peer-reviewed funding, are PI on a clinical trial, or are newly recruited and supported by institutional funds. The current research support of PCP members comprises $6.5M in peer-reviewed funding of which $4.4M (68%) is from the NCI (direct dollars.) Due to the efforts in promoting inter-disciplinary studies, a substantial component of the research funding is in the form of P50, P01, and other collaborative grants. Of the 417 newly treated prostate cancer patients, 66 (16%) were enrolled onto therapeutic clinical trials in 2013. The program published a total of 458 papers in the previous grant period. 24% were inter-institutional, 32% were intra-programmatic and 20% were inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617728
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Herman, Daniel S; Smith, Christina; Liu, Chang et al. (2018) Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog. J Mol Diagn 20:512-521
Birnbaum, Jeanette K; Duggan, Catherine; Anderson, Benjamin O et al. (2018) Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health 6:e885-e893
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Partridge, Emma K; Neuhouser, Marian L; Breymeyer, Kara et al. (2018) Comparison of Nutrient Estimates Based on Food Volume versus Weight: Implications for Dietary Assessment Methods. Nutrients 10:
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Kuzma, Jessica N; Cromer, Gail; Hagman, Derek K et al. (2018) Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans. Eur J Clin Nutr :
Yu, Hsiang; Cheng, Yu-Jen; Wang, Ching-Yun (2018) Methods for multivariate recurrent event data with measurement error and informative censoring. Biometrics 74:966-976
Puré, Ellen; Hingorani, Sunil R (2018) Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends Cancer 4:273-277
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422

Showing the most recent 10 out of 1267 publications